Half-life
~4–6 hours estimated
Evidence Level
Moderate Evidence
Mechanism of Action
Selectively activates the tissue-protective receptor (TPR) of EPO, dissociated from erythropoietic effects. Modulates innate immune response and promotes nerve fiber regeneration.
Published Research Ranges & Study Context
Studies have administered: 4–8mg 3x weekly in human phase 2 trials
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Phase 2 RCT showed significant reduction in small fiber neuropathy symptoms and improved intraepidermal nerve fiber density. Beta-cell studies show preservation in T1D models.
Moderate Evidence
Phase 1/2 human trials available
Side Effects Observed in Research
Generally well-tolerated; no significant hematological effects in trials (key differentiation from EPO)
Available Configurations (SKU Reference)
RA10
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on ARA-290 — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.